Cargando…
Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis, is yet unknown. Osteoarthritis remains a clinical challenge, associated with high disability and...
Autores principales: | Jantzen, Frederik Thal, Christensen, Rune Häckert, Chaudhry, Basit Ali, Amin, Faisal Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363275/ https://www.ncbi.nlm.nih.gov/pubmed/37489143 http://dx.doi.org/10.1159/000530138 |
Ejemplares similares
-
Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022) -
Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022) -
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021) -
Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
por: de Vries Lentsch, Simone, et al.
Publicado: (2021) -
Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)